Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update

Sensus Healthcare, Inc. (NASDAQ:SRTS) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,210,000 shares, a growth of 107.4% from the December 15th total of 583,500 shares. Approximately 9.2% of the shares of the company are short sold. Based on an average trading volume of 203,100 shares, the days-to-cover ratio is currently 6.0 days.

Hedge Funds Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC grew its position in Sensus Healthcare by 578.6% in the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after acquiring an additional 38,474 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Sensus Healthcare by 128.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after purchasing an additional 93,511 shares during the period. Renaissance Technologies LLC grew its holdings in Sensus Healthcare by 34.4% in the 2nd quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after buying an additional 100,294 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare during the second quarter worth approximately $95,000. Finally, Marshall Wace LLP boosted its position in shares of Sensus Healthcare by 152.4% in the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock valued at $412,000 after acquiring an additional 46,732 shares during the period. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Trading Up 2.8 %

NASDAQ SRTS traded up $0.18 during trading on Tuesday, reaching $6.56. 139,448 shares of the company’s stock were exchanged, compared to its average volume of 221,096. The company’s fifty day simple moving average is $7.68 and its 200-day simple moving average is $6.70. The firm has a market capitalization of $107.51 million, a PE ratio of 11.51 and a beta of 1.21. Sensus Healthcare has a fifty-two week low of $2.61 and a fifty-two week high of $9.33.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on SRTS shares. Maxim Group lifted their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th. HC Wainwright boosted their target price on Sensus Healthcare from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, November 18th.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.